Life Sciences
Top stories summarized by our editors
5/25/2018

Mentoring summer interns at Pfizer has "turned out to be a robust two-way street," writes Sally Susman, Pfizer's executive vice president of corporate affairs. Interns bring optimism, fresh perspectives, energy and humor that refresh the workplace, Susman writes.

Full Story:
Forbes
More Summaries:
Sally Susman, Pfizer
5/25/2018

Although gender and race diversity are important, cognitive diversity, which includes differences in information processing styles and perspectives, is also critical to businesses, writes Heidi Jannenga, co-founder and president of WebPT. When people with diverse knowledge come together, they adapt to change faster, learn faster, overcome challenges more effectively and overcome other social blockers that limit business success.

Full Story:
Entrepreneur online
More Summaries:
Heidi Jannenga
5/24/2018

Over-the-counter teething products that contain benzocaine pose a "serious risk to infants and children" and offer no benefit, according to an FDA warning issued Wednesday. Teething gels, sprays, ointments, solutions and lozenges that contain benzocaine could cause the potentially fatal blood condition methemoglobinemia, the FDA said, and the agency is asking manufacturers to stop marketing the products for pediatric use.

Full Story:
USA Today
More Summaries:
FDA, benzocaine, methemoglobinemia
5/24/2018

A voluntary recall was issued by Merrick Pet Care for certain Merrick Backcountry and Castor & Pollux brand dog treats after a consumer complaint of finding high levels of beef thyroid hormone in one of the products. The recalled products include Merrick Backcountry Great Plains Real Beef Jerky, Real Beef Sausage Cuts and Real Steak Patties, as well as Castor & Pollux Good Buddy Prime Patties Real Beef Recipe and Sausage Cuts Real Beef Recipe, all with best-before dates of 5/1/2017 through 9/1/2019, which were distributed to pet stores and grocery stores across the US and via online retailers.

5/24/2018

Pfizer's tafamidis, which is being developed as a treatment for patients with transthyretin cardiomyopathy, was given breakthrough therapy designation by the FDA.

Full Story:
Seeking Alpha
More Summaries:
Pfizer, FDA
5/24/2018

Cosmo Pharmaceuticals' travelers' diarrhea drug candidate Aemcolo, or rifamycin SV MMX, was accepted by the FDA for review and given a PDUFA date of Nov. 16. In a late-stage study of patients with traveler's diarrhea, treatment with Aemcolo showed noninferiority to ciprofloxacin and superiority to placebo.

Full Story:
eMPR
More Summaries:
Cosmo Pharmaceuticals
5/24/2018

A Phase II clinical study was initiated by Inovio Pharmaceuticals for its drug candidate VGX-3100 to assess its efficacy in 24 adult patients who have human papilloma virus-related anal dysplasia. The company is recruiting HIV-negative patients with histologically confirmed anal or perianal high-grade squamous intraepithelial lesions that are associated with HPV-16 and/or HPV-18.

Full Story:
PharmaBiz (India)
More Summaries:
Inovio Pharmaceuticals
5/24/2018

Abbott's Xience Sierra everolimus-eluting coronary stent system was approved by the FDA. The stent, which has longer lengths and better flexibility than its predecessors, along with the delivery system are intended to aid in the treatment of multiple or totally blocked vessels and other challenging cases.

More Summaries:
Abbott, FDA
5/24/2018

The FDA gave Zimmer Biomet clearance to market its 3D-printed Zyston Strut Open Titanium Interbody Spacer System, a family of lumbar cages designed for improving the interbody spacer's graft capacity, visualization and strength during spinal fusion procedures. The system also includes surgical tools for facilitating implant insertion, manipulation and removal.

Full Story:
Becker's Spine Review
More Summaries:
FDA
5/24/2018

BIO launched an initiative in the industry to inform CEOs and board members that diversity leads to better financial performance and approved funding to help advance biotech leadership diversity at the board level. According to a McKinsey study, firms in the top quartile for cultural and ethnic diversity on executive teams were 33% more likely to have greater profitability.